ORGANIC CHEMISTRY

FRONTIERS







View Article Online View Journal | View Issue

RESEARCH ARTICLE



Cite this: Org. Chem. Front., 2017, 4,

Selective cross-dehydrogenative C-O coupling of N-hydroxy compounds with pyrazolones. Introduction of the diacetyliminoxyl radical into the practice of organic synthesis†

Igor B. Krylov, Da Stanislav A. Paveliev, Boris N. Shelimov, Boris V. Lokshin, b Irina A. Garbuzova, b Viktor A. Tafeenko, Vladimir V. Chernyshev, c,d Alexander S. Budnikov, a,e Gennady I. Nikishina and Alexander O. Terent'ev b *a

Oxidative C-O coupling of pyrazolones with N-hydroxy compounds of different classes (N-hydroxyphthalimide, N-hydroxybenzotriazole, oximes) was achieved; both one-electron oxidants $(Fe(ClO_4)_3, (NH_4)_2Ce(NO_3)_6)$ and two-electron oxidants $(PhI(OAc)_2, Pb(OAc)_4)$ are applicable, and the yields reach 91%. Apparently, the coupling proceeds via the formation of N-oxyl radicals from N-hydroxy compounds. One of the N-oxyl intermediates, the diacetyliminoxyl radical, was found to be exclusively stable in solution in spite of being sterically unhindered; it was isolated from an oxidant and used as a new reagent for the synthesis and mechanism study. The products of C-O coupling of pyrazolones with N-hydroxyphthalimide can be easily transformed into aminooxy compounds, valuable substances for combinatorial chemistry.

Received 6th June 2017, Accepted 17th July 2017 DOI: 10.1039/c7qo00447h

rsc.li/frontiers-organic

Introduction

The development of C-C and C-heteroatom cross-dehydrogenative coupling (CDC) methods is one of the major trends in modern organic synthesis and green chemistry. Such methods avoid prefunctionalization of coupling partners (with -Hal, -OTf, -SnBu₃, -B(OH)₂, and other groups) and thus afford high atom and step economy (Scheme 1).1

C-O bonds are abundant in natural and synthetic organic compounds, which makes the development of C-O cross-dehydrogenative coupling (C-O CDC) desirable. Nevertheless, C-O CDC remains one of the most challenging types of oxidative

Traditional cross-coupling and nucleophilic substitution groups X. M must be introduced -MX $\rightarrow R^1-R^2$ Base R^1 —H + X— R^2 —Base•HX R^1 — R^2 X = Hal, OTf ... $M = BR_2$, SnR_3 , SiR_3 , ZnHal ...



Scheme 1 Traditional and cross-dehydrogenative coupling.

^aN. D. Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences, 47 Leninsky prosp., Moscow 119991, Russian Federation. E-mail: alterex@yandex.ru ^bA. N. Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences, 28 Vavilova St., Moscow 119991, Russian Federation ^cDepartment of Chemistry, M.V. Lomonosov Moscow State University,

1-3 Leninskie Gory, Moscow 119991, Russian Federation

^dA. N. Frumkin Institute of Physical Chemistry and Electrochemistry RAS.

31 Leninsky prospect, Moscow 119071, Russian Federation

^eHigher Chemical College of the Russian Academy of Sciences, Mendeleev University of Chemical Technology of Russia, 9 Miusskaya sq., Moscow 125047, Russian Federation

† Electronic supplementary information (ESI) available: Experimental details, NMR, ESR, FTIR spectral data (PDF), compound 3h (CIF). CCDC 1411623. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/ c7qo00447h

couplings^{1c-f} due to the ease of side oxidation processes. Usually a new C-O bond between two molecules is formed via reductive elimination in a metal catalyzed process or as a result of the reaction of an O-nucleophile with a C-electrophile (Scheme 2).1c O-Reagents are frequently used in excess amounts to maintain the selectivity, which limits the scope of O-reagents to simple molecules. To overcome the mentioned limitations and open new coupling possibilities, we focused our attention on O-radicals as intermediates for C-O bond formation. N-Oxyl radicals derived from the N-hydroxy compounds proved to be useful for intramolecular cyclizations,² C=C bond functionalization, oxidation, C-O CDC with alkylarenes, 5a,b β-dicarbonyl compounds, 5c,d and aldehydes. 5e,f

Nevertheless, structural diversity of C-reagents for the coupling and N-oxyl intermediates remains limited. In the present study we demonstrated the applicability of N-oxyl radicals for

$$\begin{array}{c} R^3 \\ R^2 \\ \hline \\ Reductive \ elimination \\ \hline \\ R^3 \\ \hline \\ R^2 \\ \hline \\ R^1 \\ \hline \\ C\text{-electrophile} + O\text{-nucleophile} \\ \hline \\ R^3 \\ \hline \\ C^* \\ R^1 \\ \hline \\ C\text{-electrophile} + O\text{-nucleophile} \\ \hline \\ R^3 \\ \hline \\ R^2 \\ \hline \\ R^1 \\ \hline \\ C\text{-electrophile} + O\text{-nucleophile} \\ \hline \\ R^3 \\ \hline \\ R^2 \\ \hline \\ R^1 \\ \hline \\ C\text{-electrophile} + O\text{-nucleophile} \\ \hline \\ R^3 \\ \hline \\ R^2 \\ \hline \\ R^1 \\ \hline \\ C\text{-radical} + O\text{-radical} \\ \hline \\ Present \ work \\ \hline \end{array}$$

Scheme 2 Strategies for C-O coupling

Research Article

oxidative coupling with heterocyclic compounds. Pyrazolones were chosen as heterocycle representatives because they are both challenging substrates for radical coupling due to the easiness of their oxidation and oxidative dimerization⁶ and important compounds for medicinal chemistry.

Pyrazolin-5-ones and pyrazolidine-3,5-diones are known as anti-inflammatory drugs (Chart 1), neuroprotectants and antioxidants (Edaravone), antiviral,7 antitumor,8 fungicidal and bactericidal9 compounds, HNO donors,10 agonists of farnesoid X receptor, ^{11a} AT1 angiotensin II receptor antagonists, ^{11b} and


Chart 1 Examples of bioactive compounds and drugs with pyrazolone moiety

HNO donors¹⁰

Previous works: mainly electrophilic functionalization

$$\begin{array}{c} R^2 \\ R^4 \\ X \\ R^3 \\ R^5 \\ R^5 \\ R^5 \\ R^5 \\ R^6 \\ R^7 \\$$

Present work: free-radical C-O CDC



Scheme 3 Methods for oxidative functionalization of pyrazolones.

Dyrk1A^{11c} and UDP-N-acetylenolpyruvyl glucosamine reductase^{11d} inhibitors.

Methods for pyrazolone functionalization have been intensively developed in the last few years, but almost all of them are conceptually based on the same principle, namely, electrophilic attack on position 4 of the heterocycle (Scheme 3).

Diaryliodonium salts, 12a nitroalkenes, 12b 4-oxo-4-arylbutenoates, ^{12c} alkynones, ^{12d} azodicarboxylates, ^{12e} isatin-derived N-Boc ketimines^{12f} and diacyl peroxides^{12g} were used as electrophiles. A rare example of free-radical oxidative C-S coupling of pyrazolones with thiophenols was reported (Scheme 3). 12h In the present study free-radical oxidative C-O coupling of pyrazolones with N-hydroxy compounds is reported (Scheme 3). Typical problems for O-centered radicals, harsh generation conditions and low selectivity, were successfully circumvented. A substantial insight into the nature of a free-radical coupling mechanism was achieved by the discovery of a new freeradical reagent, the diacetyliminoxyl radical, which previously was known as the only plausible intermediate.^{5d}

Results and discussion

With 4-benzyl-3-methylpyrazolin-5-one 1a, N-hydroxyphthalimide (NHPI) 2a and 3-(hydroxyimino)-2,4-pentanedione 2b as the model substrates, the influence of reaction parameters on the yield of C-O coupling products 3a and 4 was studied (Table 1).

In contrast to the previously reported coupling of NHPI with β -dicarbonyl compounds, δ the reaction with pyrazolones

Table 1 Oxidant screening for the C-O coupling of pyrazolone 1a with NHPI 2a or oxime 2b

2a (0.8 mmol) Oxidant OR OR MeCN (5 mL) HO 1a (0.8 mmol) 60 °C or rt 5-60 min 2b (0.8 mmol)

Run	Oxidant (mol/mol of 1a)	Time (min)	T (°C)	Yield (%)
Oxidat	ive C-O coupling of 1a with	NHPI 2a		
1	$Fe(ClO_4)_3 \cdot nH_2O(2)$	10	60	90
2	$Fe(ClO_4)_3 \cdot nH_2O(2)$	20	rt	72
3	$Fe(NO_3)_3 \cdot 9H_2O(2)$	20	60	< 5
4	$FeCl_3$ (2)	20	60	15
5	$(NH_4)_2Ce(NO_3)_6(2)$	20	rt	87
6	$Pb(OAc)_4(1)$	20	60	84
7	$PhI(OAc)_2(1)$	20	60	69
8	$Cu(ClO_4)_2 \cdot 6H_2O(2)$	20	60	24
9	$Mn(OAc)_3 \cdot 2H_2O(2)^a$	20	60	9
10	$KMnO_4 (0.4)^a$	20	60	35
Oxidat	ive C-O coupling of 1a with	oxime 2b		
11	$Fe(ClO_4)_3 \cdot nH_2O(2)$	10	60	91
12	$Fe(ClO_4)_3 \cdot nH_2O(2)$	20	rt	90
13	$Fe(ClO_4)_3 \cdot nH_2O(2)$	5	rt	69
14	$KMnO_4 (0.4)^a$	10	60	85
15	$Mn(OAc)_3 \cdot 2H_2O(2)^a$	10	60	52
16	$Mn(OAc)_3 \cdot 2H_2O(2)$	60	60	20
17	$Cu(ClO_4)_2 \cdot 6H_2O(2)$	10	60	36
18	$(NH_4)_2Ce(NO_3)_6(2)$	10	60	24
19	$Pb(OAc)_4(1)$	10	60	43
20	$PhI(OAc)_2$ (1)	10	60	30

^a AcOH was used as the solvent.

proceeds under the action of either single-electron oxidants (Fe(ClO₄)₃, (NH₄)₂Ce(NO₃)₆, runs 1, 2, and 5) or two-electron oxidants (Pb(OAc)₄, PhI(OAc)₂, runs 6 and 7). The highest yield was obtained with Fe(ClO₄)₃ (run 1, 90%), whereas iron(III) chloride and nitrate were inefficient (entries 3 and 4). Low yields were observed with Cu(ClO₄)₂ and manganese based oxidants (runs 8-10).

When oxime 2b was used instead of NHPI 2a, a different order of oxidant efficacy was observed (runs 11-20), Fe(ClO₄)₃ being still the best. In the case of (NH₄)₂Ce(NO₃)₆, the low yield of 4 can be attributed to the instability of iminoxyl radicals derived from oxime 2b in the presence of (NH₄)₂Ce $(NO_3)_6.^{5d}$

With the optimized conditions in hand we tested the scope of the discovered coupling (Table 2). Under universal reaction conditions (Fe(ClO₄)₃ as the oxidant, 60 °C, 10 min) pyrazolin-5-ones 1 reacted smoothly with N-hydroxy compounds of different classes: NHPI (products 3a-3i), oximes (products 4-16), and N-hydroxybenzotriazole (products 17-18). Lower yields were obtained in the reaction of NHPI with pyrazolones containing a phenyl substituent (products 3h and 3i). We pro-

Table 2 The scope of pyrazolones 1 and N-hydroxy compounds 2 for oxidative C-O coupling

R ¹	F	Fe(CIO ₄) ₃	R ¹			
HN N HO		(3 mmol)	N CO			
	2a-h rt-60	eCN (5 mL) °C, 10-20 min	R ² R ³ N			
(1.5 mmol) (1.5	5 mmol) 3a.	R ³ = Ph, 90% ^a , 8	3a-i,4-18 37% ^b			
N O N	∭ 3b,	$R^3 = Allyl, 78\%^a$				
3c, R ³ = <i>i</i> -Pr, 80% ^a , 82% ^b 3d, R ³ = <i>n</i> -Bu, 80% ^a						
	3e , I—NH	$R^3 = n - C_6 H_{13}, 85$	wa N−NH			
N-NH O n-Pr		N-N	Ph			
N O	N PO	N ₂ O	N			
		0	0			
3f , 68% ^a 3g , 6	9% ^a , 41% ^b	3h , 36% ^a , 34% ^d 57% ^c , 45% ^d	o, 3i , 36% ^b , 60% ^c			
NH -	NH	N NH	NNH			
Ph Ph	ON I	Ph	Ph			
N		0 0	0			
0 0			_N _N _N			
4 , 91% ^a	5 , 29% ^a	6 , 45% ^a	7, 66% ^a			
N NH	N, NH	N NH	N			
		O N	NH			
N	0, N		O_N 			
	OEt		t-Bu t-Bu			
0, 7270	, E/Z = 8/1, 18%	,	11 , 65% ^a			
NNH	NNH	NNH	N N Ph			
i-Pr O n-l	O N	n-C ₆ H ₁₃ O N	O N			
Ö Ö 12 , 77% ^a	Ö Ö 13 , 84% ^a	0 Ö 14 , 77% ^a	⊍ ს 15 , 83% ^a			
H_o \	N. H.	M ✓	H O			
N N	0	N	0 N			
16, 68% ^a	Ph 17 , 79	N-N	Pr N N N N N N N N N N N N N N N N N N N			

^a Fe(ClO₄)₃ was added to a stirred mixture of pyrazolone and N-hydroxy compound at 60 °C, reaction time was 10 min b (NH₄)₂Ce(NO₃)₆ was added to a stirred mixture of pyrazolone and NHPI at room temperature, reaction time was 20 min ^c Mixing order changed: pyrazolone **1h-i** was added portion wise to the stirred mixture of NHPI and $(NH_4)_2Ce(NO_3)_6$ in MeCN at room temperature. ^d Mixing order changed: pyrazolone 1h was added portion wise to the stirred mixture of NHPI and Fe(ClO₄)₃ in MeCN at 60 °C.

posed that these pyrazolones are oxidized faster than NHPI with the formation of side products. Indeed, when the reagent addition order was changed and NHPI was mixed with an oxidant to generate *N*-oxyl radicals before the addition of pyrazolones, the yields of products **3h** and **3i** substantially increased (Table 2, yields with notes c and d).

In the row of *N*-hydroxy compounds the yield depends on the stability of the corresponding *N*-oxyl radicals. The lowest yield was obtained with the oxime of ethyl pyruvate (18%, product 9).

Pyrazolidine-3,5-dione **19**, known as the anti-inflammatory drug phenylbutazone, reacts with NOH-compounds **2** analogously to pyrazolin-5-ones **1** (Scheme 4).

A plausible mechanism of the oxidative coupling of pyrazolones with *N*-hydroxy compounds is depicted in Scheme 5. *N*-Oxyl radicals are generated from *N*-hydroxy compounds under the action of an oxidant. Then two sequences are possible: the attack of an *N*-oxyl radical on pyrazolone (**A**) followed by oxidation or oxidation of pyrazolone (**B**) followed by the addition of the radical.

The formation of *N*-oxyl radicals from NHPI under the action of used oxidants was confirmed by EPR spectroscopy (Scheme 6 and ESI†). The formation of iminoxyl radicals from oxime **2b** under analogous conditions was reported earlier. ^{5d}

Scheme 4 The oxidative C-O coupling of pyrazolidine-3,5-dione 19 with N-hydroxy compounds 2a, b, and h.

Scheme 5 Possible pathways of the oxidative C–O coupling of pyrazolones with *N*-hydroxy compounds.

Scheme 6 Generation of phthalimide-*N*-oxyl radicals (PINO) from NHPI.

Diacetyliminoxyl free radical

The detection of a free radical under the reaction conditions does not prove its participation in the process and does not reveal its exact role. It is desirable to directly observe the "individual" reactivity of radicals in the absence of other reagents, such as oxidants used for their generation, which is usually impossible due to the high reactivity of free radicals, including sterically unhindered *N*-oxyl radicals with acceptor groups. To solve this problem, a method for the synthesis of diacetyliminoxyl radical 21,¹³ a plausible intermediate, was developed (Scheme 7).

Oxidation of **2b** with Pb(OAc)₄ gave rise to oxime radical **21** with almost quantitative yield based on EPR (see the ESI†). Radical **21** turned out to be surprisingly stable despite being sterically unhindered; it tolerated column chromatography on silica gel and the resulting dark red solution of **21** in CH₂Cl₂ (*ca.* 0.04 M) was stored at room temperature for 2–5 days without a significant decomposition detectable by EPR or FTIR spectroscopy. As far as we know it is record stability for the unhindered oxime radical that was not reported previously.¹³

Oxime radical **21** reacted with pyrazolones **1a**, **c**, **i**, and **h** giving C–O coupling products **4**, **12**, **15**, and **16**, respectively, and oxime **2b** (Scheme 8). Apparently, one equivalent of **21** formed the product and another one played the role of the oxidant. The yields are close to that obtained with *in situ* generation of iminoxyl radicals using $Fe(ClO_4)_3$ (see Table 2). These results are convincing evidence in favor of the mechanism depicted in Scheme 5.

It should be noted that the structure of the synthesized radical **21** has little in common with known stable *N*-oxyl radicals (Chart 2). The majority of the stable *N*-oxyl radicals are amine-*N*-oxyl radicals. Only some representatives of this extensive type of radicals are depicted. This class includes both

Scheme 7 Synthesis of diacetyliminoxyl radical 21

Scheme 8 The reaction of diacetyliminoxyl radical 21 with pyrazolin-5ones




Chart 2 Examples of known stable N-oxyl radicals and synthesized radical 21.

cyclic structures (TEMPO, 14 AZADO, 15 ABNO, 16 IAPNO, 17 nitronyl nitroxides¹⁸) and acyclic structures (Fremy's salt, 19 bis (trifluoromethyl)nitroxide, 20 TIPNO and others 21). These *N*-oxyl radicals found wide use in various fields 22a,b including oxidation processes, 15b,16a,17,22a-d "living" radical polymerization, 21b,c,22a spin-labeling 22e and synthesis of magnetic materials. 18b,c,22f Stable oxime radicals (imine-N-oxyl type) are very rare and highly hindered, examples are di-tert-butyliminoxyl radical and di(1-adamantyl)iminoxyl radical (Chart 2).²³ An important feature of radical 21 is its synthetic accessibility: the parent oxime can be prepared in one simple step from acetylacetone, NaNO2 and H2SO4.24

Synthetic application of the coupling products

Finally, the synthetic utility of some of the synthesized products was tested (Scheme 9). Novel O-substituted hydroxyl-

Scheme 9 The synthetic utility of the synthesized oxidative C-O coupling products.

amines 24a, c, d, and f were synthesized from products 3a, c, d, and f without the need for chromatographic purification. In the case of the product 3a one-pot deprotection/condensation sequence was demonstrated to obtain oxime ether 25.

Conclusions

In conclusion, a new type of oxidative C-O coupling was realized, the method was applied to a wide range of N-hydroxy compounds and pyrazolones. N-Oxyl radicals are identified as key intermediates that selectively add to position 4 of the pyrazolone ring. The first method for the synthesis of the diacetyliminoxyl radical in solution was proposed. This radical can be used as an easily available reagent and a model radical for mechanistic studies.

Experimental

Iron(III) perchlorate hydrate reagent grade (Alfa Aesar, anhydrous basis purity ca. 65%), Fe(NO₃)₃·9H₂O 99+%, FeCl₃ 98% anhydrous, (NH₄)₂Ce(NO₃)₆ 99%, Pb(OAc)₄ 95%, PhI(OAc)₂ 98%, Cu(ClO₄)₂·6H₂O 98%, Mn(OAc)₃·2H₂O 95%, KMnO₄ 99%, N-hydroxyphthalimide 98%, N-hydroxybenzotriazole hydrate 98% (11–26% H₂O), 2,2,6,6-tetramethylpiperidinyloxyl (TEMPO) 98%, benzaldehyde 98+%, N₂H₄·H₂O (64% hydrazine), 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione (phenylbutazone) 99+%, NH₂OH·HCl 99%, and NaHCO₃ 99% were used as is from commercial sources. CH2Cl2 was distilled prior to use. MeCN and EtOAc were distilled over P2O5. Glacial acetic acid was used as is from commercial sources. Preparation of the starting pyrazolones and oximes is described in the ESI.†

General reaction conditions for oxidative C-O coupling of 1a with NHPI 2a (Table 1)

To a mixture of 4-benzyl-3-methylpyrazolin-5-one 1a (150 mg, 0.797 mmol), N-hydroxyphthalimide 2a (130 mg, 0.797 mmol) and solvent (5 mL) stirred at given temperature, an oxidant (50.4-874 mg, 0.4-2 mol/mol of 1a) was added for 5-20 seconds; stirring was continued at the same temperature for 20 min

The reaction mixture was cooled to room temperature, diluted with CH₂Cl₂ (10 mL) and water (20 mL) and shaken.

The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (2 × 10 mL), and all organic extracts were combined. In the case of an intensive color of extract indicative of the presence of metal complexes, it was additionally washed with an aqueous solution of $Na_2S_2O_4$ (200 mg in 20 mL of water). Organic extract was washed with water (2 × 20 mL), dried over Na_2SO_4 , and rotary evaporated under water-jet vacuum. C–O coupling product 3a was isolated by column chromatography on silica gel using the EtOAc/ CH_2Cl_2 eluent; the volume part of EtOAc was gradually increased from 0 to 20%.

4-Benzyl-3-methyl-4-(phthalimide-*N*-oxy)pyrazolin-5-one 3a. White powder, mp = 176–177 °C. ¹H NMR (300.13 MHz, CDCl₃) δ: 8.18 (bs, 1H), 7.93–7.82 (m, 2H), 7.82–7.72 (m, 2H), 7.32–7.15 (m, 5H), 3.55 (d, J = 13.1 Hz, 1H), 3.43 (d, J = 13.1 Hz, 1H), 2.27 (s, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ: 171.0, 163.8, 157.5, 135.0, 131.2, 130.0, 128.9, 128.8, 127.9, 124.1, 87.8, 38.3, 14.7. IR (KBr) ν (cm⁻¹): 3200, 3108, 1802, 1751, 1370, 1359, 1342, 1309, 1187, 1070, 1015, 1002, 952, 872, 745, 700, 566, 558, 520. Elemental analysis calcd (%) for C₁₉H₁₅N₃O₄: C, 65.32; H, 4.33; N, 12.03. Found: C, 65.14; H, 4.31; N, 11.94.

General reaction conditions for oxidative C–O coupling of 1a with oxime 2b (Table 1)

To a mixture of 4-benzyl-3-methylpyrazolin-5-one **1a** (150 mg, 0.797 mmol), 3-(hydroxyimino)-2,4-pentanedione **2b** (103 mg, 0.797 mmol) and solvent (5 mL) stirred at 60 °C, an oxidant (50.4–874 mg, 0.4–2 mol/mol **1a**) was added for 5–20 seconds; stirring was continued at 60 °C for 10 min. The coupling product **4** was isolated as described above for **3a**.

3-(((4-Benzyl-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)oxy) imino)pentane-2,4-dione 4. White powder, mp = 139–140 °C.

¹H NMR (300.13 MHz, CDCl₃) δ : 8.26 (bs, 1H), 7.35–7.22 (m, 3H), 7.22–7.09 (m, 2H), 3.26 (d, J = 13.4 Hz, 1H), 3.17 (d, J = 13.4 Hz, 1H), 2.41 (s, 3H), 2.28 (s, 3H), 2.00 (s, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 197.0, 193.5, 173.4, 158.7, 158.3, 131.0, 130.0, 128.8, 128.1, 87.3, 38.0, 30.7, 25.9, 14.1. IR (KBr) ν (cm⁻¹): 3178, 3114, 1734, 1692, 1366, 1298, 1049, 1017, 1009, 942, 755, 700. Elemental analysis calcd (%) for C₁₆H₁₇N₃O₄: C, 60.94; H, 5.43; N, 13.33. Found: C, 60.91; H, 5.39; N, 13.41.

General reaction conditions for Table 2 and Scheme 4

General procedure a (all experiments in Scheme 4 and experiments in Table 2 with note a): to a mixture of pyrazolone (1.5 mmol), N-hydroxy compound (1.5 mmol) and MeCN (5 mL) stirred at 60 °C, Fe(ClO₄)₄·nH₂O (3 mmol) was added; stirring was continued for 10 min at 60 °C.

General procedure b (experiments in Table 2 with note b): to a mixture of pyrazolone (1.5 mmol), N-hydroxy compound (1.5 mmol) and MeCN (5 mL) stirred at room temperature, $(NH_4)_2Ce(NO_3)_6$ (3 mmol) was added; stirring was continued for 20 min at room temperature.

General procedure c (experiments in Table 2 with note c): to a mixture of N-hydroxyphthalimide (1.5 mmol) and MeCN (5 mL) stirred at room temperature, $(NH_4)_2Ce(NO_3)_6$ (3 mmol) was added for 5–10 seconds, stirring was continued for 4 min, and then pyrazolone (1.5 mmol) was added portion wise for

7–10 min; after the complete addition of pyrazolone, stirring was continued for 5 min at room temperature.

General procedure d (experiments in Table 2 with note d): to a mixture of N-hydroxyphthalimide (1.5 mmol) and MeCN (5 mL) stirred at 60 °C, Fe(ClO₄)₄·nH₂O (3 mmol) was added for 5–10 seconds, and then pyrazolone (1.5 mmol) was added portion wise for 1 min; stirring was continued for 5 min at 60 °C.

The products 3a-i, 4-18, 20a, b, and h were isolated as described for 3a in experiment in Table 1.

4-Allyl-3-methyl-4-(phthalimide-*N*-oxy)pyrazolin-5-one 3b. White powder, mp = 154–155 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ: 11.29 (bs, 1H), 7.89 (m, 4H), 5.56–5.33 (m, 1H), 5.25 (d, J = 16.7 Hz, 1H), 5.15 (d, J = 10.3 Hz, 1H), 2.87 (dd, J₁ = 7.0 Hz, J₂ = 12.9 Hz, 1H), 2.74 (dd, J₁ = 7.0 Hz, J₂ = 12.9 Hz, 1H), 2.12 (s, 3H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ: 170.4, 163.3, 155.9, 135.2, 128.3, 123.6, 121.4, 86.1, 35.6, 13.8. IR (KBr) ν (cm⁻¹): 3374, 1795, 1750, 1732, 1367, 1350, 1308, 875, 711, 700. HR-MS (ESI): m/z = 322.0786, calcd for C₁₅H₁₃N₃O₄ + Na⁺: 322.0798.

4-(Isopropyl)-3-methyl-4-(phthalimide-*N***-oxy)pyrazolin-5-one 3c.** White powder, mp = 188–188.5 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ: 11.15 (bs, 1H), 7.87 (m, 4H), 2.43–2.22 (m, 1H), 2.13 (s, 3H), 1.08 (d, J = 6.7 Hz, 3H), 1.01 (d, J = 6.9 Hz, 3H). 13 C NMR (75.47 MHz, DMSO-d₆) δ: 170.4, 163.0, 156.7, 135.2, 128.1, 123.5, 90.3, 31.1, 15.9, 14.62, 14.57. IR (KBr) ν (cm⁻¹): 3297, 1796, 1748, 1731, 1467, 1375, 1349, 1188, 1055, 992, 874, 708. Elemental analysis calcd (%) for $C_{15}H_{15}N_3O_4$: C, 59.80; H, 5.02; N, 13.95. Found: C, 59.51; H, 5.09; N, 14.07.

4-(Butyl)-3-methyl-4-(phthalimide-*N*-oxy)pyrazolin-5-one 3d. White powder, mp = 168–168.5 °C. 1 H NMR (300.13 MHz, CDCl₃) δ: 8.48 (bs, 1H), 7.88–7.78 (m, 2H), 7.78–7.70 (m, 2H), 2.25–2.11 (m, 1H), 2.22 (s, 3H), 2.03 (td, $J_{\rm t}$ = 12.5, $J_{\rm d}$ = 4.9, 1H), 1.45–1.26 (m, 2H), 1.26–0.98 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H). 13 C NMR (75.47 MHz, CDCl₃) δ: 171.4, 163.8, 158.3, 134.9, 129.0, 124.0, 87.8, 31.4, 24.4, 22.7, 14.0, 13.8. IR (KBr) ν (cm⁻¹): 3303, 1794, 1752, 1467, 1377, 1351, 1314, 1188, 1017, 1001, 944, 876, 707, 650, 630, 606, 562, 520. Elemental analysis calcd (%) for C₁₆H₁₇N₃O₄: C, 60.94; H, 5.43; N, 13.33. Found: C, 60.93; H, 5.40; N, 13.18.

4-(Hexyl)-3-methyl-4-(phthalimide-*N*-oxy)pyrazolin-5-one 3e. White powder, mp = 121–122 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ : 11.27 (bs, 1H), 7.88 (m, 4H), 2.10 (s, 3H), 2.04–1.91 (m, 2H), 1.38–1.13 (m, 6H), 1.13–0.91 (m, 2H), 0.84 (t, J = 6.4 Hz, 3H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ : 170.9, 163.3, 156.5, 135.1, 128.3, 123.5, 87.2, 30.9, 30.8, 28.4, 21.8, 21.7, 13.8, 13.5. IR (KBr) ν (cm⁻¹): 3219, 2961, 2929, 1799, 1740, 1468, 1456, 1439, 1363, 1346, 1303, 1188, 1075, 1016, 994, 939, 874, 753, 707, 563, 521. HR-MS (ESI): m/z = 366.1417, calcd for $C_{18}H_{21}N_3O_4 + Na^+$: 366.1424.

2-((3-Oxo-2,3,4,5,6,7-hexahydro-3aH-indazol-3a-yl)oxy)isoindoline-1,3-dione 3f. White powder, mp = 180–182 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ : 11.25 (bs, 1H), 7.87 (m, 4H), 2.73–2.40 (m, 2H), 2.40–2.20 (m, 1H), 2.17–1.90 (m, 2H), 1.81–1.62 (m, 1H), 1.62–1.25 (m, 2H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ : 171.6, 163.3, 159.0, 135.2, 128.3, 123.6, 82.8, 32.5,

27.3, 27.0, 19.7. IR (KBr) ν (cm $^{-1}$): 3187, 1796, 1739, 1713, 1363, 1347, 1308, 1187, 1104, 1015, 1000, 956, 875, 791, 748, 705, 676, 606, 563, 521. HR-MS (ESI): m/z=300.0988, calcd for $C_{15}H_{13}N_3O_4+H^+$: 300.0979.

2-((4-Methyl-5-oxo-3-propyl-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) isoindoline-1,3-dione 3g. White powder, mp = 156.5–157.5 °C.

¹H NMR (300.13 MHz, CDCl₃) δ : 8.61 (bs, 1H), 7.94–7.64 (m, 4H), 2.77–2.61 (m, 1H), 2.51–2.35 (m, 1H), 1.85–1.68 (m, 2H), 1.65 (s, 3H), 1.03 (t, J = 7.4 Hz, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 172.2, 163.9, 161.6, 134.9, 129.0, 124.0, 84.3, 29.7, 18.6, 18.1, 14.0. IR (KBr) ν (cm⁻¹): 3270, 1795, 1742, 1709, 1468, 1368, 1355, 1311, 1187, 1162, 1109, 1076, 975, 874, 752, 702, 671, 650, 607, 588, 565, 520. Elemental analysis calcd (%) for C₁₅H₁₅N₃O₄: C, 59.80; H, 5.02; N, 13.95. Found: C, 59.83; H, 4.93; N, 13.90.

3,4-Dimethyl-1-phenyl-4-(phthalimide-*N*-oxy)pyrazolin-5-one 3h. White powder, mp = 133–136 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 7.91–7.78 (m, 4H), 7.78–7.68 (m, 2H), 7.36 (t, J = 7.9 Hz, 2H), 7.16 (t, J = 7.4 Hz, 1H), 2.37 (s, 3H), 1.76 (s, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 168.0, 163.9, 158.5, 137.6, 134.9, 129.0, 125.5, 124.1, 118.9, 86.6, 18.4, 13.7. IR (KBr) ν (cm⁻¹): 1792, 1747, 1720, 1595, 1499, 1465, 1399, 1364, 1311, 1186, 1146, 1121, 1080, 1065, 962, 876, 763, 751, 704, 690, 573, 519. HR-MS (ESI): m/z = 372.0942, calcd for C₁₉H₁₅N₃O₄ + Na⁺: 372.0955.

4-Methyl-3-phenyl-4-(phthalimide-*N*-oxy)pyrazolin-5-one 3i. White powder, mp = 206–208 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ: 11.91 (bs, 1H), 8.09–7.94 (m, 2H), 7.94–7.79 (m, 4H), 7.62–7.39 (m, 3H), 1.75 (s, 3H, CH₃). ¹³C NMR (75.47 MHz, DMSO-d₆) δ: 171.8, 163.4, 154.7, 135.1, 130.3, 129.5, 128.8, 128.4, 126.1, 123.5, 83.7, 19.3. IR (KBr) ν (cm⁻¹): 3281, 1743, 1733, 1720, 1372, 1362, 1349, 1188, 1083, 970, 876, 771, 696, 649, 520. HR-MS (ESI): m/z = 358.0794, calcd for C₁₈H₁₃N₃O₄ + Na[†]: 358.0798.

2-(((4-Benzyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)-5,5-dimethylcyclohexane-1,3-dione 5. Slightly yellow powder, mp = 145–147 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 8.22 (s, 1H), 7.29 (m, 5H), 3.44–3.09 (m, 2H), 2.92–2.43 (m, 4H), 1.95 (s, 3H), 1.18 (s, 3H), 1.06 (s, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 192.4, 190.3, 173.8, 158.9, 151.2, 131.6, 130.2, 128.7, 127.9, 88.3, 55.2, 54.3, 38.2, 30.5, 29.6, 27.7, 14.3. IR (KBr) ν (cm⁻¹): 3356, 3321, 1735, 1693, 1620, 1570, 1255, 1213, 1030, 1006, 989, 957, 758, 730, 699, 632, 598, 578, 571, 555. Elemental analysis calcd (%) for C₁₉H₂₁N₃O₄: C, 64.21; H, 5.96; N, 11.82. Found: C, 63.98; H, 5.78; N, 11.72.

5-(((4-Benzyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)-2,2-dimethyl-1,3-dioxane-4,6-dione 6. Slightly yellow powder, mp = 150–152 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 8.27 (bs, 1H), 7.40–7.15 (m, 5H), 3.49–3.28 (m, 2H), 1.98 (s, 3H), 1.83 (s, 3H), 1.80 (s, 3H). 13 C NMR (75.47 MHz, CDCl₃) δ : 172.9, 157.9, 155.8, 150.7, 136.7, 131.0, 130.2, 128.8, 128.2, 116.7, 106.5, 89.5, 38.0, 28.8, 27.7, 14.3. IR (KBr) ν (cm⁻¹): 3231, 1782, 1756, 1730, 1577, 1395, 1385, 1301, 1268, 1240, 1227, 1201, 1085, 1044, 1020, 976, 932, 891, 758, 729, 702. Elemental analysis calcd (%) for C₁₇H₁₇N₃O₆: C, 56.82; H, 4.77; N, 11.69. Found: C, 56.71; H, 4.70; N, 11.59.

5-(((4-Benzyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)-1,3-dimethylpyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione 7. White powder, mp = 164–166 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ : 11.10 (s, 1H), 7.52–7.10 (m, 5H), 3.49–3.05 (m, 2H), 3.17 (s, 3H), 3.15 (s, 3H), 1.88 (s, 3H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ : 173.0, 157.2, 156.7, 152.7, 150.4, 137.2, 132.0, 130.1, 128.2, 127.4, 88.6, 36.9, 28.4, 27.9, 13.7. IR (KBr) ν (cm⁻¹): 3308, 1740, 1692, 1676, 1450, 1419, 1378, 1292, 1051, 1011, 927, 749. Elemental analysis calcd (%) for C₁₇H₁₇N₅O₅: C, 54.98; H, 4.61; N, 18.86. Found: C, 54.90; H, 4.63; N, 18.83.

3-(((3,4-Dimethyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)imino) pentane-2,4-dione 8. White powder, mp = 106–107 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ: 11.25 (bs, 1H), 2.33 (s, 3H), 2.21 (s, 3H), 1.96 (s, 3H), 1.41 (s, 3H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ: 197.6, 193.1, 173.8, 158.5, 157.3, 83.6, 30.1, 25.4, 16.9, 12.6. IR (KBr) ν (cm⁻¹): 3322, 1742, 1716, 1687, 1364, 1298, 1204, 1190, 1125, 1067, 964, 929, 681, 619, 583, 564. Elemental analysis calcd (%) for C₁₀H₁₃N₃O₄: C, 50.21; H, 5.48; N, 17.57. Found: C, 50.08; H, 5.20; N, 17.48.

Ethyl 2-(((3,4-dimethyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)propanoate 9. Mixture of E and Z isomers, E/Z = 8/1; configuration was determined by NOESY, NMR signal assignment was made based on the HMBC NMR experiment (see the ESI \dagger). White powder, mp = 82–85 °C. ¹H NMR (300.13 MHz, DMSO-d₆): major *E* isomer δ : 11.07 (bs, 1H, NH), 4.24–4.13 (m, 2H, OCH₂), 2.04 (s, 3H, CH₃-C=N-O), 1.89 (s, 3H, CH₃-C=N-NH), 1.40 (s, 3H, CH₃-C-O-N), 1.21 (t, J = 7.1 Hz, 3H, CH_3 - CH_2); minor Z isomer δ : 11.02 (bs, 1H, NH), 4.37-4.24 (m, 2H, OCH₂), 1.95 (s, 3H, CH₃-C=N-O), 1.88 (s, 3H, CH₃-C=N-NH), 1.27 (t, J = 7.1 Hz, 3H, CH₃-CH₂), 1.26 (s, 3H, CH₃-C-O-N). ¹³C NMR (75.47 MHz, DMSO-d₆): major E isomer δ: 174.6 (HN-C=O), 162.4 (O-C=O), 159.2 (C=N-NH), 152.0 (C=N-O), 82.6 (C-O-N), 61.5 (OCH_2) , 17.4, 13.9, 12.5, 11.6 (CH₃); minor Z isomer δ : 17.1, 16.2, 12.4. IR (KBr) ν (cm⁻¹): 3222, 1717, 1432, 1374, 1329, 1308, 1204, 1178, 1151, 1124, 1006, 932, 863, 754, 673, 570. Elemental analysis calcd (%) for C₁₀H₁₅N₃O₄: C, 49.79; H, 6.27; N, 17.42. Found: C, 49.71; H, 6.25; N, 17.40.

5-(((3,4-Dimethyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)imino)-2,2-dimethyl-1,3-dioxane-4,6-dione 10. White powder, mp = 143–146 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ : 11.31 (bs, 1H), 1.95 (s, 3H), 1.71 (s, 3H), 1.70 (s, 3H), 1.52 (s, 3H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ : 173.5, 158.2, 156.0, 150.5, 137.1, 105.9, 85.4, 27.6, 27.4, 16.9, 12.6. IR (KBr) ν (cm⁻¹): 3330, 1778, 1738, 1570, 1399, 1387, 1373, 1314, 1296, 1271, 1244, 1197, 1157, 1110, 1057, 1036, 984, 952, 911, 894, 794, 638, 629, 568. Elemental analysis calcd (%) for C₁₁H₁₃N₃O₆: C, 46.65; H, 4.63; N, 14.84. Found: C, 46.40; H, 4.43; N, 14.80.

4,5-Dimethyl-4-(((2,2,4,4-tetramethylpentan-3-ylidene)amino) oxy)-2,4-dihydro-3*H***-pyrazol-3-one 11.** White powder, mp = 143–144 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 8.22 (bs, 1H), 1.96 (s, 3H), 1.44 (s, 9H), 1.39 (s, 3H), 1.12 (s, 9H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 176.7, 171.2, 162.3, 82.1, 40.7, 38.8, 29.9, 29.8, 17.6, 13.1. IR (KBr) ν (cm⁻¹): 3215, 3104, 3010, 2991, 2975, 2956, 2931, 2872, 1710, 1625, 1482, 1448, 1433, 1392,

1381, 1369, 1311, 1195, 1122, 1075, 1024, 970, 892, 868, 746, 673, 574. Elemental analysis calcd (%) for $C_{14}H_{25}N_3O_2$: C, 62.89; H, 9.43; N, 15.72. Found: C, 62.83; H, 9.56; N, 15.55.

3-(((4-Isopropyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)pentane-2,4-dione 12. Slightly yellow viscous gum. 1 H NMR (300.13 MHz, CDCl₃) δ : 8.64 (bs, 1H), 2.38 (s, 3H), 2.33–2.15 (m, 1H), 2.27 (s, 3H), 1.98 (s, 3H), 1.08 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H). 13 C NMR (75.47 MHz, CDCl₃) δ : 197.0, 193.6, 173.7, 159.2, 158.1, 89.4, 31.0, 30.5, 25.8, 16.0, 14.6, 14.1. IR (thin layer) ν (cm⁻¹): 3280, 2975, 2940, 2923, 1727, 1696, 1609, 1469, 1421, 1392, 1364, 1295, 1192, 1089, 1051, 1004, 944, 756, 718, 690, 678, 629, 615, 569, 548. Elemental analysis calcd (%) for C₁₂H₁₇N₃O₄: C, 53.92; H, 6.41; N, 15.72. Found: C, 53.80; H, 6.48; N, 15.68.

3-(((4-Butyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)pentane-2,4-dione 13. White powder, mp = 42–43 °C.

¹H NMR (300.13 MHz, CDCl₃) δ : 8.30 (bs, 1H), 2.38 (s, 3H), 2.28 (s, 3H), 2.04–1.89 (m, 1H), 2.00 (s, 3H), 1.87–1.72 (m, 1H), 1.44–1.10 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H).

¹³C NMR (75.47 MHz, CDCl₃) δ : 197.0, 193.6, 174.0, 159.5, 158.1, 87.2, 31.1, 30.6, 25.9, 23.8, 22.7, 13.8, 13.4. IR (KBr) ν (cm⁻¹): 3267, 2961, 2934, 2874, 1729, 1697, 1421, 1364, 1293, 1185, 1082, 1047, 1008, 982, 936, 697, 620, 586, 567. Elemental analysis calcd (%) for C₁₃H₁₉N₃O₄: C, 55.51; H, 6.81; N, 14.94. Found: C, 55.25; H, 6.97; N, 14.70.

3-(((4-Hexyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)pentane-2,4-dione 14. White powder, mp = 62–63 °C.

¹H NMR (300.13 MHz, CDCl₃) δ : 8.44 (bs, 1H), 2.37 (s, 3H), 2.27 (s, 3H), 2.05–1.89 (m, 1H), 2.00 (s, 4H), 1.86–1.71 (m, 1H), 1.39–1.12 (m, 8H), 0.86 (t, J = 6.6 Hz, 3H).

¹³C NMR (75.47 MHz, CDCl₃) δ : 197.0, 193.6, 174.0, 159.5, 158.1, 87.2, 31.43, 31.37, 30.6, 29.2, 25.9, 22.5, 21.7, 14.1, 13.4. IR (KBr) ν (cm⁻¹): 3204, 3120, 2955, 2932, 2860, 1729, 1696, 1459, 1427, 1385, 1363, 1293, 1183, 1082, 1062, 1050, 1021, 1003, 935, 767, 717, 620, 591, 563, 542. Elemental analysis calcd (%) for C₁₅H₂₃N₃O₄: C, 58.24; H, 7.49; N, 13.58. Found: C, 58.10; H, 7.55; N, 13.49.

3-(((3,4-Dimethyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl) oxy)imino)pentane-2,4-dione 15. Slightly yellow gum. 1 H NMR (300.13 MHz, CDCl₃) δ : 7.92–7.84 (m, 2H), 7.48–7.37 (m, 2H), 7.25–7.17 (m, 1H), 2.40 (s, 3H), 2.20 (s, 3H), 2.15 (s, 3H), 1.60 (s, 3H). 13 C NMR (75.47 MHz, CDCl₃) δ : 197.0, 193.5, 170.2, 159.8, 158.1, 137.7, 129.1, 125.6, 118.8, 86.0, 30.6, 25.9, 17.8, 13.0. IR (thin layer) ν (cm $^{-1}$): 1728, 1697, 1596, 1502, 1398, 1367, 1312, 1293, 1239, 1194, 1151, 1119, 1090, 1066, 1023, 968, 929, 907, 759, 692. HR-MS (ESI): m/z = 338.1112, calcd for $C_{16}H_{17}N_3O_4 + Na^+$: 338.1111.

3-(((4-Methyl-5-oxo-3-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)oxy) imino)pentane-2,4-dione 16. White powder, mp = 112–113 °C.

¹H NMR (300.13 MHz, CDCl₃) δ: 8.93 (bs, 1H), 7.84–7.70 (m, 2H), 7.52–7.34 (m, 3H), 2.43 (s, 3H), 2.20 (s, 3H), 1.72 (s, 3H).

¹³C NMR (75.47 MHz, CDCl₃) δ: 197.0, 193.7, 174.5, 158.0, 157.8, 131.0, 129.2, 129.1, 126.2, 84.4, 30.8, 25.9, 19.7. IR (KBr) ν (cm⁻¹): 3200, 3120, 1736, 1708, 1691, 1630, 1359, 1297, 1216, 1118, 982, 754, 723, 695, 635, 618, 552, 516. HR-MS (ESI): m/z = 324.0952, calcd for C₁₅H₁₅N₃O₄ + Na⁺: 324.0955.

4-((1*H*-Benzo[*d*][1,2,3]triazol-1-yl)oxy)-4-benzyl-5-methyl-2,4-dihydro-3*H*-pyrazol-3-one 17. Slightly yellow powder, mp = 158–161 °C. ¹H NMR (300.13 MHz, DMSO-d₆) δ: 11.09 (s, 1H), 8.08–8.01 (m, 1H), 7.91–7.83 (m, 1H), 7.71–7.61 (m, 1H), 7.52–7.43 (m, 1H), 7.39–7.24 (m, 5H), 3.65 (d, J = 12.9 Hz, 1H), 3.50 (d, J = 12.9 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (75.47 MHz, DMSO-d₆) δ: 170.6, 156.0, 142.1, 131.0, 130.0, 128.8, 128.5, 127.8, 127.7, 125.4, 119.5, 110.3, 90.8, 36.8, 14.4. IR (KBr) ν (cm⁻¹): 3294, 1743, 1711, 1081, 993, 769, 754, 744, 731, 697, 672, 637, 569. Elemental analysis calcd (%) for C₁₇H₁₅N₅O₂: C, 63.54; H, 4.71; N, 21.79. Found: C, 63.16; H, 4.38; N, 21.50.

4-((1*H***-Benzo[***d***][1,2,3]triazol-1-yl)oxy)-4-isopropyl-5-methyl-2,4-dihydro-3***H***-pyrazol-3-one 18.** White powder, mp = 110–111 °C. ¹H NMR (300.13 MHz, CDCl₃) δ: 8.28 (bs, 1H), 7.95–7.86 (m, 1H), 7.84–7.75 (m, 1H), 7.54–7.43 (m, 1H), 7.40–7.29 (m, 1H), 2.66–2.46 (m, 1H), 2.42 (s, 3H), 1.30 (d, J = 6.8 Hz, 3H), 1.08 (d, J = 7.0 Hz, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ: 171.1, 158.5, 143.0, 128.6, 125.1, 119.9, 110.5, 92.7, 31.9, 16.1, 15.1, 14.5. IR (KBr) ν (cm⁻¹): 3309, 3124, 2973, 1734, 1726, 1704, 1467, 1445, 1379, 1281, 1240, 1196, 1157, 1100, 1073, 1042, 996, 784, 766, 745, 687, 638, 622, 573, 545, 431. Elemental analysis calcd (%) for C₁₃H₁₅N₅O₂: C, 57.13; H, 5.53; N, 25.63. Found: C, 57.03; H, 5.48; N, 25.58.

2-((4-Butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)oxy)isoindoline-1,3-dione 20a. Slightly yellow powder, mp = 156–158 °C.

¹H NMR (300.13 MHz, CDCl₃) δ: 7.89–7.80 (m, 2H), 7.80–7.72 (m, 2H), 7.43–7.14 (m, 10H), 2.52–2.34 (m, 2H), 1.54–1.33 (m, 4H), 0.93 (t, J = 6.6 Hz, 3H).

¹³C NMR (75.47 MHz, CDCl₃) δ: 165.3, 163.4, 135.0, 134.8, 129.2, 128.9, 127.7, 124.0, 123.6, 83.7, 33.0, 24.9, 22.8, 13.8. IR (KBr) ν (cm⁻¹): 1794, 1762, 1741, 1726, 1594, 1493, 1372, 1353, 1319, 1295, 1265, 1188, 1175, 1125, 980, 877, 755, 744, 708, 691, 523. Elemental analysis calcd (%) for C₂₇H₂₃N₃O₅: C, 69.07; H, 4.94; N, 8.95. Found: C, 68.69; H, 5.01; N, 8.91.

4-Butyl-4-(((2,4-dioxopentan-3-ylidene)amino)oxy)-1,2-diphenyl-pyrazolidine-3,5-dione 20b. Slightly yellow powder, mp = 47–49 °C. 1 H NMR (300.13 MHz, CDCl₃) δ: 7.45–7.31 (m, 8H), 7.30–7.20 (m 2H), 2.41 (s, 3H), 2.25 (s, 3H), 2.22–2.12 (m, 2H), 1.54–1.30 (m, 4H), 0.91 (t, J = 6.7 H, 3H). 13 C NMR (75.47 MHz, CDCl₃) δ: 196.0, 193.0, 168.0, 157.9, 135.4, 129.3, 127.5, 122.5, 83.8, 32.8, 30.6, 26.0, 24.3, 22.7, 13.7. IR (KBr) ν (cm⁻¹): 2960, 2932, 1768, 1732, 1696, 1596, 1488, 1460, 1420, 1360, 1292, 1176, 1104, 1084, 1048, 1024, 1004, 928, 760, 740, 716, 692, 636, 624, 556, 500. HR-MS (ESI): m/z = 458.1676, calcd for $C_{24}H_{25}N_3O_5 + Na^+$: 458.1686.

4-((1*H*-Benzo[*d*][1,2,3]triazol-1-yl)oxy)-4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione 20h. Slightly yellow powder, mp = 130–131 °C. ¹H NMR (300.13 MHz, CDCl₃) δ: 8.01–7.91 (m, 1H), 7.78–7.70 (m, 1H), 7.57–7.45 (m, 1H), 7.42–7.10 (m, 11H), 2.57–2.43 (m, 2H), 1.73–1.41 (m, 4H), 0.99 (t, J = 7.0 Hz, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ: 165.6, 143.3, 134.5, 129.2, 128.8, 127.9, 125.2, 123.7, 120.0, 110.0, 86.3, 33.6, 24.4, 22.8, 13.8. IR (KBr) ν (cm⁻¹): 2960, 2928, 2872, 2860, 1760, 1728, 1596, 1488, 1460, 1440, 1380, 1348, 1312, 1280, 1236, 1172, 1156, 1080, 1052, 780, 760, 744, 692. HR-MS (ESI): m/z = 464.1685, calcd for $C_{25}H_{23}N_5O_3 + Na^+$: 464.1693.

Generation of phthalimide-*N*-oxyl radical from *N*-hydroxyphthalimide (experimental details for Scheme 6)

An oxidant (quantities are given below) was added to a 0.002 M solution of *N*-hydroxyphthalimide in MeCN (20 mL) at room temperature (18–23 °C), and the mixture was shaken until the complete dissolution of the oxidant; the EPR spectrum of the solution was registered 5–15 min after mixing. Following oxidants were used: $(NH_4)_2Ce(NO_3)_6$ (21.9 mg, 0.04 mmol), $Fe(ClO_4)_3 \cdot nH_2O$ (*ca.* 35% H_2O , 21.8 mg, 0.04 mmol), $Cu(ClO_4)_2 \cdot 6H_2O$ (14.8 mg, 0.04 mmol), $Pb(OAc)_4$ (8.9 mg, 0.02 mmol), $PhI(OAc)_2$ (6.4 mg, 0.02 mmol). The triplet EPR spectrum characteristic of the phthalimide-*N*-oxyl radical was observed in all cases (see the ESI† for details).

Generation and characterization of diacetyliminoxyl radical 21 (experimental details for Scheme 7)

All experiments with diacetyliminoxyl radical 21 were conducted at room temperature (18–23 °C).

Diacetyl oxime 2b (258 mg, 2 mmol) was dissolved in CH₂Cl₂ (4 mL) at 18-23 °C, and then Pb(OAc)₄ (467 mg, 1 mmol) was added with vigorous stirring. The mixture immediately turned dark red, stirring was continued for 10 min, and then the mixture was transferred to the chromatographic column, prepared by suspending the silica gel (12 g) in excess of CH2Cl2. CH2Cl2 was used as an eluent, and the fraction corresponding to the dark-red spot was collected, so that the volume of the fraction was 50 mL. The obtained solution of diacetyliminoxyl radical 21 in CH_2Cl_2 (50 mL, $C \approx$ 0.04 mmol mL⁻¹ according to quantitative EPR measurement, see the ESI†) was used for experiments described below. The stability and purity of 21 in solution was confirmed by EPR, FT-IR spectroscopy and ICP-MS (to confirm separation from the lead compounds); for spectral data and discussion, see the ESI.†

Reactions of diacetyliminoxyl radical 21 with pyrazolin-5-ones 1a, 1c, 1h, and 1i (experimental details for Scheme 8)

To a stirred solution of diacetyliminoxyl radical **21** in CH_2Cl_2 (50 mL, ca. 0.04 mol L^{-1} , \approx 2 mmol, prepared as described above), pyrazolin-5-one (1 mmol; **1a**: 188.2 mg; **1c**: 140.2 mg; **1h**: 188.2 mg; **1i**: 174.2 mg) was added at room temperature (18–23 °C). Stirring was continued for 3 h, and gradual dissolution of pyrazolin-5-one and the decrease in the intensity of the red color of the solution were observed. The mixture was rotary evaporated under water-jet vacuum, an aliquot (20 mg) of the residue was analyzed by 1H and ^{13}C NMR, and the rest was transferred to a silica gel chromatographic column and eluted with EtOAc/CH₂Cl₂ (EtOAc content was increased gradually from 0 to 30 vol%) to isolate the reaction products. In the case of pyrazolin-5-one **1h**, an additional experiment was performed with a reaction time of 24 h (instead of 3 h), and the same product yields were observed.

The ¹H and ¹³C NMR spectra of the reaction mixtures of diacetyliminoxyl radical **21** with pyrazolones **1a**, **c**, **h**, and **i** are given in the ESI.† Signals were assigned to the coupling pro-

ducts (4, 12, 15 and 16) and oxime 2b by comparing the spectra of reaction mixtures with the spectra of individual compounds. No significant impurity signals were observed.

Experimental details for Scheme 9

General procedure for the synthesis of hydroxylamines 24. The product of C-O coupling 3 (180-210 mg, 0.6 mmol), NH₂OH·HCl (83.4 mg, 1.2 mmol), MeCN (3 mL) and H₂O (0.5 mL) were placed in a 10 mL round-bottom flask. Then NaHCO₃ (101 mg, 1.2 mmol) was added with vigorous stirring at room temperature; stirring was continued for 1 h. The mixture was rotary evaporated to dryness, and the residue was extracted with CH2Cl2 (3 × 7 mL). Combined extracts were washed with NaHCO₃ (2 × 3 mL), dried over MgSO₄, and rotary evaporated. Et₂O (1-2 mL) was added to the residue to cause crystallization, and then was rotary evaporated. Hydroxylamines 24a, c, d, and f were obtained as white powders.

4-(Aminooxy)-4-benzyl-5-methyl-2,4-dihydro-3*H*-pyrazol-3-one **24a.** White powder, mp = 55–57 °C. ¹H NMR (300.13 MHz, CDCl₃) δ: 8.60 (bs, 1H), 7.36–7.19 (m, 3H), 7.19–7.04 (m, 2H), 5.63 (bs, 2H), 3.05 (d, J = 13.3 Hz, 1H), 2.96 (d, J = 13.3 Hz, 1H), 2.02 (s, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ: 175.6, 160.4, 132.3, 130.0, 128.5, 127.6, 88.0, 38.6, 14.2. IR (KBr) ν (cm⁻¹): 3313, 3247, 3174, 3107, 1717, 1455, 1435, 1147, 1072, 757, 737, 701, 640, 577, 562. HR-MS (ESI): m/z = 220.1082, calcd for C₁₁H₁₃N₃O₂ + H⁺: 220.1081.

4-(Aminooxy)-4-isopropyl-5-methyl-2,4-dihydro-3*H*-pyrazol-3-one **24c.** White powder, mp = 100-102 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 10.74 (s, 1H), 6.23 (s, 2H), 1.96–1.80 (m, 1H), 1.93 (s, 3H), 0.89 (d, J = 6.6 Hz, 3H), 0.78 (d, J = 7.1 Hz, 3H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 175.5, 159.4, 88.7, 30.4, 16.1, 14.6, 13.9. HR-MS (ESI): m/z = 172.1074, calcd for $C_7H_{13}N_3O_2 + H^+$: 172.1081. IR (KBr) ν (cm⁻¹): 3296, 3226, 3150, 1730, 1591, 1293, 1282, 1161, 1083, 1069, 732, 667, 559.

4-(Aminooxy)-4-butyl-5-methyl-2,4-dihydro-3*H*-**pyrazol-3-one 24d.** White powder, mp = 89–90 °C. ¹H NMR (300.13 MHz, CDCl₃) δ: 8.68 (bs, 1H), 5.49 (bs, 2H), 2.03 (s, 3H), 1.84–1.66 (m, 1H), 1.65–1.48 (m, 1H), 1.41–1.00 (m, 4H), 0.86 (t, J = 7.1 Hz, 3H). 13 C NMR (75.47 MHz, CDCl₃) δ: 176.1, 161.3, 87.6, 31.7, 24.1, 22.8, 13.8, 13.5. IR (KBr) ν (cm $^{-1}$): 3299, 3233, 2961, 2926, 1731, 1595, 1248, 1166, 1080, 1072, 1059, 757, 748, 692, 643, 580, 562. HR-MS (ESI): m/z = 186.1239, calcd for $C_8H_{15}N_3O_2 + H^+$: 186.1237.

3a-(Aminooxy)-2,3a,4,5,6,7-hexahydro-3*H*-indazol-3-one 24f. White powder, mp = 111–112 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 9.10 (bs, 1H), 5.53 (bs, 2H), 2.74–2.54 (m, 1H), 2.54–2.33 (m, 1H), 2.26–1.98 (m, 2H), 1.84–1.54 (m, 2H), 1.53–1.30 (m, 2H). ¹³C NMR (75.47 MHz, CDCl₃) δ : 176.5, 164.5, 83.4, 33.9, 28.9, 27.4, 20.3. IR (KBr) ν (cm⁻¹): 3288, 3175, 2943, 2925, 1719, 1677, 1619, 1225, 1171, 1146, 1111, 1024, 1008, 741, 683, 651, 595, 574. HR-MS (ESI): m/z = 192.0745, calcd for $C_7H_{11}N_3O_2 + Na^+$: 192.0743.

(E)-Benzaldehyde-O-(4-benzyl-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)oxime 25. $N_2H_4\cdot H_2O$ (32.2 mg, 0.644 mmol) and MeCN (3 mL) were placed in a 10 mL round-bottom flask, then

2-((4-benzyl-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)isoindoline-1,3-dione 3a (150 mg, 0.429 mmol) was added with intensive stirring, that was continued for 40 min at room temperature, and precipitate formation was observed. Benzaldehyde (182 mg, 1.72 mmol) was added, and the precipitate gradually dissolved. Stirring was continued for 2 h at room temperature, and then the mixture was rotary evaporated to dryness. The product was isolated by column chromatography on silica gel using a EtOAc/CH2Cl2 mixture as the eluent with a gradual change in the ratio of solvents from 0 to 1/10. (E)-Benzaldehyde-O-(4-benzyl-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)oxime 25 was obtained as a white powder (93 mg, 0.303 mmol, 70%). Signal assignment in ¹H and ¹³C NMR spectra, as well as defining configuration of the C=N bond was performed with the aid of 2D NMR experiments, HMBC and NOESY (see the ESI†). Mp = 120-121 °C. ¹H NMR (300.13 MHz, CDCl₃) δ : 10.88 (bs, 1H, NH), 8.46 (s, 1H, HC=N), 7.58-7.50 (m, 2H, ArH), 7.47-7.37 (m, 3H, ArH), 7.33–7.17 (m, 5H, ArH), 3.21 (d, J = 12.9 Hz, 1H, CH₂), 3.09 (d, J = 12.9 Hz, 1H, CH₂), 1.97 (s, 3H, CH₃). ¹³C NMR (75.47 MHz, CDCl₃) δ : 174.2 (CONH), 158.1 (C=N-N), 151.8 (C=N-O), 132.3, 130.9, 130.7, 129.9, 128.9, 128.2, 127.2 (Ph), 86.0 (C-O-N), 37.2 (CH₂), 13.7 (CH₃). IR (KBr) ν (cm⁻¹): 3417, 3221, 3065, 1732, 1702, 1455, 1377, 1161, 1076, 1016, 921, 758, 749, 697, 628, 570, 519, 510. Elemental analysis calcd (%) for C₁₈H₁₇N₃O₂: C, 70.34; H, 5.58; N, 13.67. Found: C, 70.31; H, 5.62; N, 13.59.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

This work was supported by the Russian Foundation for Basic Research (Grant 15-29-05828). Authors would like to thank Dr Roman Novikov for 2D NMR experiments and the ZIOC-Interlab-Analytik Jena International Analytical Center for ICP-MS analysis by Analytik Jena PlasmaQuant MS Elite.

Notes and references

- (a) C.-J. Li, Acc. Chem. Res., 2009, 42, 335; (b) C. S. Yeung and V. M. Dong, Chem. Rev., 2011, 111, 1215; (c) I. B. Krylov, V. A. Vil' and A. O. Terent'ev, Beilstein J. Org. Chem., 2015, 11, 92; (d) C. Zhang, C. Tang and N. Jiao, Chem. Soc. Rev., 2012, 41, 3464; (e) R. Samant, K. Match and A. P. Antonchick, Eur. J. Org. Chem., 2013, 5769; (f) E. M. Beccalli, G. Broggini, M. Martinelli and S. Sottocornola, Chem. Rev., 2007, 107, 5318.
- 2 (a) B. C. Giglio and E. J. Alexanian, *Org. Lett.*, 2014, **16**, 4304; (b) R. K. Quinn, V. A. Schmidt and E. J. Alexanian, *Chem. Sci.*, 2013, **4**, 4030; (c) F. Chen, X.-L. Yang, Z.-W. Wu and B. Han, *J. Org. Chem.*, 2016, **81**, 3042; (d) Y.-Y. Liu,

- X.-H. Yang, J. Yang, R.-J. Song and J.-H. Li, *Chem. Commun.*, 2014, **50**, 6906; (*e*) X.-X. Peng, Y.-J. Deng, X.-L. Yang, L. Zhang, W. Yu and B. Han, *Org. Lett.*, 2014, **16**, 4650; (*f*) B. Han, X.-L. Yang, R. Fang, W. Yu, C. Wang, X.-Y. Duan and S. Liu, *Angew. Chem., Int. Ed.*, 2012, **51**, 8816; (*g*) X. Zhu, Y.-F. Wang, W. Ren, F.-L. Zhang and S. Chiba, *Org. Lett.*, 2013, **15**, 3214; (*h*) B. C. Lemercier and J. G. Pierce, *Org. Lett.*, 2015, **17**, 4542.
- 3 (a) X.-F. Xia, S.-L. Zhu, Z. Gu, H. Wang, W. Li, X. Liu and Y.-M. Liang, J. Org. Chem., 2015, 80, 5572; (b) R. Bag, D. Sar and T. Punniyamurthy, Org. Biomol. Chem., 2016, 14, 3246; (c) X.-F. Xia, Z. Gu, W. Liu, H. Wang, Y. Xia, H. Gao, X. Liu and Y.-M. Liang, J. Org. Chem., 2015, 80, 290; (d) J. Zhang and Y. Tang, Adv. Synth. Catal., 2016, 358, 752; (e) X.-F. Xia, S.-L. Zhu, Y.-N. Niu, D. Zhang, X. Liu and H. Wang, Tetrahedron, 2016, 72, 3068; (f) B. C. Giglio, V. A. Schmidt and E. J. Alexanian, J. Am. Chem. Soc., 2011, 133, 13320; (g) R. Bag, D. Sar and T. Punniyamurthy, Org. Lett., 2015, 17, 2010.
- 4 (a) F. Recupero and C. Punta, Chem. Rev., 2007, 107, 3800;
 (b) L. Melone and C. Punta, Beilstein J. Org. Chem., 2013, 9, 1296;
 (c) Y. Amaoka, S. Kamijo, T. Hoshikawa and M. Inoue, J. Org. Chem., 2012, 77, 9959;
 (d) R. Lin, F. Chen and N. Jiao, Org. Lett., 2012, 14, 4158.
- 5 (a) J. M. Lee, E. J. Park, S. H. Cho and S. Chang, J. Am. Chem. Soc., 2008, 130, 7824; (b) A. O. Terent'ev, I. B. Krylov, M. Y. Sharipov, Z. M. Kazanskaya and G. I. Nikishin, Tetrahedron, 2012, 68, 10263; (c) A. O. Terent'ev, I. B. Krylov, V. P. Timofeev, Z. A. Starikova, V. M. Merkulova, A. I. Ilovaisky and G. I. Nikishin, Adv. Synth. Catal., 2013, 355, 2375; (d) I. B. Krylov, A. O. Terent'ev, V. P. Timofeev, B. N. Shelimov, R. A. Novikov, V. M. Merkulova and G. I. Nikishin, Adv. Synth. Catal., 2014, 356, 2266; (e) M. Dinda, C. Bose, T. Ghosh and S. Maity, RSC Adv., 2015, 5, 44928; (f) H. Yao, Y. Tang and K. Yamamoto, Tetrahedron Lett., 2012, 53, 5094.
- 6 (a) X. Sheng, J. Zhang, H. Yang and G. Jiang, Org. Lett., 2017, 19, 2618; (b) S. Veibel, Acta Chem. Scand., 1972, 26, 3685.
- 7 (a) V. Hadi, Y.-H. Koh, T. W. Sanchez, D. Barrios, N. Neamati and K. W. Jung, Bioorg. Med. Chem. Lett., 2010, 20, 6854; (b) R. Ramajayam, K.-P. Tan, H.-G. Liu and P.-H. Liang, Bioorg. Med. Chem. Lett., 2010, 7849; (c) R. Srinivasan, B. Narayana, B. K. Sarojini, V. Bhanuprakash, C. G. D. Raj and P. S. Nayak, Lett. Drug Des. Discovery, 2016, 13, 149.
- (a) X.-Y. Zhang, Y.-F. Gu, T. Chen, D.-X. Yang, X.-X. Wang, B.-L. Jiang, K.-P. Shao, W. Zhao, C. Wang, J.-W. Wang, Q.-R. Zhang and H.-M. Liu, *MedChemComm*, 2015, 6, 1781;
 (b) S. Wu, Y. Li, G. Xu, S. Chen, Y. Zhang, N. Liu, G. Dong, C. Miao, H. Su, W. Zhang and C. Sheng, *Eur. J. Med. Chem.*, 2016, 115, 141–147.
- A. Dandia and A. K. Jain, *J. Heterocycl. Chem.*, 2013, 50, 104.
 (a) S. Nourian, R. P. Lesko, D. A. Guthrie and J. P. Toscano, *Tetrahedron*, 2016, 72, 6037; (b) S. Nourian, Z. A. Zilber and J. P. Toscano, *J. Org. Chem.*, 2016, 81, 9138;

- (c) D. A. Guthrie, N. Y. Kim, M. A. Siegler, C. D. Moore and J. P. Toscano, *J. Am. Chem. Soc.*, 2012, 134, 1962.
- 11 (a) G. Deng, W. Li, J. Shen, H. Jiang, K. Chen and H. Liu, Bioorg. Med. Chem. Lett., 2008, 18, 5497; (b) B. Le Bourdonnec, E. Meulon, S. Yous, J.-F. Goossens, R. Houssin and J.-P. Hénichart, J. Med. Chem., 2000, 43, 2685; (c) K. A. Koo, N. D. Kim, Y. S. Chon, M.-S. Jung, B.-J. Lee, J. H. Kim and W.-J. Song, Bioorg. Med. Chem. Lett., 2009, 19, 2324; (d) M. Gilbert, A. Failli, J. Shumsky, Y. Yang, A. Severin, G. Singh, W. Hu, D. Keeney, P. J. Petersen and A. H. Katz, J. Med. Chem., 2006, 49, 6027.
- 12 (a) S. Mao, X. Geng, Y. Yang, X. Qian, S. Wu, J. Han and L. Wang, RSC Adv., 2015, 5, 36390; (b) Y.-H. Liao, W.-B. Chen, Z.-J. Wu, X.-L. Du, L.-F. Cun, X.-M. Zhang and W.-C. Yuan, Adv. Synth. Catal., 2010, 352, 827; (c) Z. Wang, Z. Yang, D. Chen, X. Liu, L. Lin and X. Feng, Angew. Chem., Int. Ed., 2011, 50, 4928; (d) Z. Wang, Z. Chen, S. Bai, W. Li, X. Liu, L. Lin and X. Feng, Angew. Chem., Int. Ed., 2012, 51, 2776; (e) Z. Yang, Z. Wang, S. Bai, X. Liu, L. Lin and X. Feng, Org. Lett., 2011, 13, 596; (f) X. Bao, B. Wang, L. Cui, G. Zhu, Y. He, J. Qu and Y. Song, Org. Lett., 2015, 17, 5168; (g) A. O. Terent'ev, V. A. Vil', E. S. Gorlov, O. N. Rusina, A. A. Korlyukov, G. I. Nikishin and W. Adam, ChemistrySelect, 2017, 2, 3334; (h) P. Sun, D. Yang, W. Wei, L. Jiang, Y. Wang, T. Dai and H. Wang, Org. Chem. Front., 2017, 4, 1367.
- 13 (a) C. Lagercrantz and K. Torssell, *Ark. Kemi*, 1967, **29**, 203; (b) S. Hoffman, A. Jezierski and B. Jezowska-Trzebiatowska, *Bull. Pol. Acad. Sci., Chem.*, 1986, **34**, 251.
- 14 O. L. Lebelev and S. N. Kazarnovskii, *Zh. Obshch. Khim.*, 1960, **30**, 1631.
- (a) R.-M. Dupeyre and A. Rassat, *Tetrahedron Lett.*, 1975, 16,
 1839; (b) M. Shibuya, M. Tomizawa, I. Suzuki and Y. Iwabuchi, *J. Am. Chem. Soc.*, 2006, 128, 8412.
- 16 (a) M. B. Lauber and S. S. Stahl, ACS Catal., 2013, 3, 2612;
 (b) R.-M. Dupeyre and A. Rassat, J. Am. Chem. Soc., 1966,
 88, 3180; (c) M. Shibuya, M. Tomizawa, Y. Sasano and Y. Iwabuchi, J. Org. Chem., 2009, 74, 4619.
- 17 S. Bar, J. N. Kumar, M. Amar, H. Toledo, R. J. Batrice and A. M. Szpilman, *ChemCatChem*, 2015, 7, 1129.

- (a) J. H. Osiecki and E. F. Ullman, J. Am. Chem. Soc., 1968,
 90, 1078; (b) C. Hirel, K. E. Vostrikova, J. Pecaut,
 V. I. Ovcharenko and P. Rey, Chem. Eur. J., 2001, 7, 2007;
 (c) E. V. Tretyakov and V. I. Ovcharenko, Russ. Chem. Rev.,
 2009, 78, 971.
- 19 H. Zimmer, D. C. Lankin and S. W. Horgan, *Chem. Rev.*, 1971, 71, 229.
- 20 W. D. Blackley and R. R. Reinhard, J. Am. Chem. Soc., 1965, 87, 802.
- 21 (a) V. A. Reznikov, I. A. Gulorov, Yu. V. Gatilov, T. V. Rybalova and L. B. Volodarsky, Russ. Chem. Bull., 1996, 45, 384; (b) D. Benoit, V. Chaplinski, R. Braslau and C. J. Hawker, J. Am. Chem. Soc., 1999, 121, 3904; (c) S. Grimaldi, J.-P. Finet, F. Le Moigne, A. Zeghdaoui, P. Tordo, D. Benoit, M. Fontanille and Y. Gnanou, Macromolecules, 2000, 33, 1141.
- (a) E. G. Bagryanskaya and S. R. A. Marque, *Chem. Rev.*, 2014, 114, 5011; (b) I. B. Krylov, M. O. Kompanets, K. V. Novikova, I. O. Opeida, O. V. Kushch, B. N. Shelimov, G. I. Nikishin, D. O. Levitsky and A. O. Terent'ev, *J. Phys. Chem. A*, 2016, 120, 68; (c) J. M. Bobbitt, C. BrüCkner and N. Merbouh, in *Organic Reactions*, ed. S. E. Denmark, *et al.*, John Wiley and Sons, 2010, ch. 2, vol. 74, DOI: 10.1002/0471264180.or074.02; (d) R. Ciriminna and M. Pagliaro, *Org. Process Res. Dev.*, 2010, 14, 245; (e) E. S. Babaylova, A. A. Malygin, A. A. Lomzov, D. V. Pyshnyi, M. Yulikov, G. Jeschke, O. A. Krumkacheva, M. V. Fedin, G. G. Karpova and E. G. Bagryanskaya, *Nucleic Acids Res.*, 2016, 44, 7935; (f) M. V. Fedin, S. L. Veber, E. G. Bagryanskaya and V. I. Ovcharenko, *Coord. Chem. Rev.*, 2015, 289–290, 341.
- 23 (a) J. L. Brokenshire, G. D. Mendenhall and K. U. Ingold, J. Am. Chem. Soc., 1971, 93, 5278; (b) K. U. Ingold, in Stable Radicals: Fundamentals and Applied Aspects of Odd-Electron Compounds, ed. R. G. Hicks, John Wiley & Sons, Ltd, Chichester, UK, 2010, ch. 6, pp. 231–244. DOI: 10.1002/ 9780470666975.ch6.
- 24 P. A. Nikitina, L. G. Kuz'mina, V. P. Perevalov and I. I. Tkach, *Tetrahedron*, 2013, **69**, 3249.